|
Title |
|
Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants
|
| Authors | | Buller, Harry R. Halperin, J L. Prins, M. |
|
Published in |
|
Journal of Thrombosis and Haemostasis. 2008, vol. 6, no. 2, p. 227-9 |
|
Keywords |
|
Anticoagulants/standards/therapeutic use — Bias (Epidemiology) — Case Management — Clinical Trials, Phase III as Topic/methods/standards — Cost-Benefit Analysis — Double-Blind Method — Fibrinolytic Agents/standards/therapeutic use — Heparin/therapeutic use — Heparin, Low-Molecular-Weight/therapeutic use — Humans — Patient Selection — Professional Practice — Prothrombin Time/instrumentation — Quality of Life — Randomized Controlled Trials as Topic/methods/standards — Thrombophilia/drug therapy — Treatment Outcome — Vitamin K/antagonists & inhibitors |
| Identifiers | | PMID: 18034770 |
|
Full text |
|
 Article (Accepted version) (72 Kb) -  Limited access to UNIGE
|
|
Structures |
|
|
| Research groups | | Geneva Platelet Group (13)
La maladie thromboembolique veineuse (808)
|
Citation
(ISO format) | | BULLER, Harry R. et al. Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants. In: Journal of Thrombosis and Haemostasis, 2008, vol. 6, n° 2, p. 227-9. doi: 10.1111/j.1538-7836.2007.02848.x https://archive-ouverte.unige.ch/unige:1856 |
Titles list
Scientific Article
unige:1856 
352 hits 
0 download 
Contact an author
Update